Analysts expect that OVID THERAPEUTC (NASDAQ:OVID) will post earnings per share (EPS) of ($0.34) for the current quarter, according to Zacks. Zero analysts have provided estimates for OVID THERAPEUTC’s earnings. The business is expected to report its next quarterly earnings report on Tuesday, September 12th.
According to Zacks, analysts expect that OVID THERAPEUTC will report full-year earnings of ($3.33) per share for the current financial year, with EPS estimates ranging from ($4.65) to ($2.00). For the next financial year, analysts expect that the company will post earnings of ($2.49) per share, with EPS estimates ranging from ($2.55) to ($2.43). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for OVID THERAPEUTC.
OVID THERAPEUTC (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, June 13th. The company reported ($3.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by $2.61.
OVID has been the subject of a number of analyst reports. JMP Securities initiated coverage on OVID THERAPEUTC in a research note on Tuesday, May 30th. They issued an “outperform” rating and a $26.00 price target for the company. William Blair initiated coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They set an “outperform” rating for the company. Citigroup Inc. initiated coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They set a “buy” rating and a $21.00 price objective for the company. Finally, Cowen and Company initiated coverage on OVID THERAPEUTC in a research report on Tuesday, May 30th. They set an “outperform” rating for the company.
Shares of OVID THERAPEUTC (NASDAQ OVID) traded down 3.72% during midday trading on Friday, reaching $10.60. The company’s stock had a trading volume of 65,506 shares. The company’s market cap is $260.77 million. OVID THERAPEUTC has a 12 month low of $10.05 and a 12 month high of $15.93. The company’s 50-day moving average price is $13.47 and its 200-day moving average price is $13.47.
About OVID THERAPEUTC
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OVID THERAPEUTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OVID THERAPEUTC and related companies with MarketBeat.com's FREE daily email newsletter.